ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting
April 21 2015 - 7:35AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
results of a series of preclinical studies on its investigational
tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at the
American Association for Cancer Research (AACR) Annual Meeting
2015. Brigatinib is in development for the treatment of patients
with anaplastic lymphoma kinase positive (ALK+) metastatic
non-small cell lung cancer (NSCLC), who are resistant to
crizotinib.
These data were included in two presentations: “Discovery of
AP26113, a potent, orally active inhibitor of anaplastic lymphoma
kinase and clinically relevant mutants” and “The potent ALK
inhibitor AP26113 can overcome mechanisms of resistance to first
and second-generation ALK TKIs in preclinical models.”
Oral Presentation on Brigatinib
Discovery
An oral presentation describes, for the first time, the design
and chemical structure of brigatinib, discovered using ARIAD’s
structure-based drug design platform. With the goal of designing a
selective ALK inhibitor with broad-based activity against
crizotinib-resistant mutants, ARIAD scientists advanced a series of
novel compounds culminating in the identification of brigatinib.
Brigatinib incorporates unique chemical-design features, including
the distinctive use of a recognition element that confers favorable
pharmacologic properties. Brigatinib has at least 10-fold greater
potency than crizotinib against ALK+ NSCLC cell lines and was
broadly active against clinically relevant crizotinib-resistant
mutants in preclinical models.
New Preclinical Data on Brigatinib in
Poster Presentation
A poster presentation shows that brigatinib, at clinically
achievable concentrations, has potent anti-tumor activity against a
panel of 17 distinct ALK mutants known to confer resistance to
other ALK inhibitors. In a separate study designed to model the
occurrence of brain metastases in ALK+ lung cancer patients,
brigatinib significantly reduced the tumor burden in mice with ALK+
brain tumors compared to the tumors in mice treated with
crizotinib. Survival of brigatinib-treated mice was also markedly
enhanced compared to the survival duration of crizotinib-treated
mice.
“These preclinical data highlight key attributes of brigatinib,
including its unique design features and its potential to address
two major causes of resistance to other ALK inhibitors: ALK point
mutations and the occurrence of brain metastases, ” said Timothy P.
Clackson, Ph.D., president of research and development and chief
scientific officer at ARIAD. “As the Phase 2 ALTA trial of
brigatinib continues to enroll patients, we look forward to
reporting additional clinical data on this internally discovered
TKI.”
About Non-Small Cell Lung Cancer and ALK
Non-small cell lung cancer (NSCLC) is the most common form of
lung cancer, accounting for approximately 85 percent of the
estimated 228,190 new cases of lung cancer diagnosed each year in
the United States, according to the American Cancer Society.
Anaplastic lymphoma kinase (ALK) was first identified as a
chromosomal rearrangement in anaplastic large-cell lymphoma (ALCL).
Genetic studies indicate that abnormal expression of ALK is a key
driver of certain types of NSCLC as well. Since ALK is generally
not expressed in normal adult tissues, it represents a promising
molecular target for cancer therapy. Approximately three to eight
percent of patients with NSCLC have the ALK gene mutation.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements. Any
statements contained herein which do not describe historical facts,
including, but not limited to, statements regarding: preclinical
data for brigatinib and additional clinical data from our Phase 2
ALTA clinical trial of brigatinib, are forward-looking statements
which are based on management's expectations and are subject to
certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These factors, risks and uncertainties include, among others:
preclinical data and early-stage clinical data may not be
replicated in later-stage clinical studies; the costs associated
with our research, development, manufacturing and other activities;
the adequacy of our capital resources and the availability of
additional funding; our ongoing and additional clinical trials of
brigatinib may not be successful or initiated, enrolled or
conducted in a timely manner; regulatory developments and safety
issues; competitive risks; manufacturing issues and those
additional factors detailed in our public filings with the U.S.
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form
10-Q. Except as otherwise noted, these forward-looking statements
speak only as of the date of this press release and we undertake no
obligation to update or revise any of these statements to reflect
events or circumstances occurring after this press release. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. All
forward‐looking statements in this press release are qualified in
their entirety by this cautionary statement.
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor MediaLiza Heapes,
617-620-4888Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2023 to Sep 2024